Lupine Publishers| Beyond The Local Anesthesia

 Lupine Publishers| LOJ Pharmacology & Clinical Research (LOJPCR)

Editorial

One of the most important events in dentistry history was the discovery of local anesthetics in 1859 by Albert Niemann (1834 – 1861). In fact, this event represents the beginning of a new era in dentistry. Despite the adverse and lethal effects of cocaine, the first local anesthetic used in dentistry, this finding permitted the develop of other local anesthetics with less adverse effects and better safety index such as procaine, lidocaine, mepivacaine, bupivacaine, prilocaine and more recently ropivacaine and articaine. Local anesthetics constitute a group of elementary drugs in the professional arsenal of dentistry and are the most used drugs in this area. They act by preventing the conduction of the nociceptive electrical impulses in a reversible way, generating a loss of sensitivity to pain. Local anesthetics internally block Na+ voltage gated channels on neuronal fibers, thus decreasing nerve conduction. Na+ voltage gated channels are complex structures formed by two β subunits (β1 and β2) and a large α subunit in whose central part is located the entry pore for this ion.

In the last 100 years, the reversible local anesthetic effect added to the wide therapeutic index of these agents have allowed to perform invasive procedures in the oral cavity in different areas such as endodontics, oral and maxillofacial surgery, implantology, restorative dentistry and periodontics without pain during the performance of these treatments. This fact has meant an unprecedented advance in the world history of dentistry.

Several research have been conducted and published with the aim of improving the pharmacokinetic profile of these drugs such as inclusion complexes with cyclodextrins and encapsulation in liposomes and nanocapsules. These studies are aimed at increasing the liposolubility of these drugs through the neuronal cell membrane, as well as avoiding the use of vasoconstrictors that are present in most local anesthetic formulations to counteract the vasodilator effect of these drugs. Moreover, this new formulations could reduce the side effects of this drugs, because these cell carriers act as reservoir and from there they release (in a sustained manner) the local anesthetics molecules. These latest advances could allow in the near future the topical use of these agents and limit the use of dental needles for their administration.

Recently, there has been special attention in relation to the cytotoxic effects produced by local anesthetics. It has been shown, for example, that these agents in low tissue concentrations (as used in clinical practice) produce an induction of cellular apoptosis. This fact could mean a possible coadjuvant treatment to the base treatment of some types of cancer. Could it be that we are facing a group of old drugs with a new target?

Read More About Lupine Publishers LOJ Pharmacology & Clinical Research (LOJPCR) Please Click on Below Link:  https://lupine-publishers-pharmacology.blogspot.com/

Journal of Pharmacology-Lupine Publishers

Reversal of Rocuronium-Induced NeuromuscularBlock with Neostigmine in the Libyan Patients by
Boyd L Summers in LOJPCR in Lupine Publishers.

Acetylcholinesterase (AChE) is catalyzing the quick hydrolysis of acetylcholine (ACh) to acetate and choline. The main biological function is being annihilation of impulse transmission at cholinergic synapses. In addition, AChE is believed to have nonclassical roles in nerve and muscle growth and in hematopoiesis [1,2]. Additionally, AChE has been concerned in Alzheimer’s disease [3,4], hypersensitivity to pesticides and Gulf War syndrome [5]. Rocuronium is frequently used non-depolarizing neuromuscular blocking agents (NMBAs) to facilitate tracheal intubation and affording muscle relaxation throughout surgery. Patients receiving these agents are at danger of outstanding curarization, which is a cause of postoperative pulmonary complications and might augment postoperative mortality [6,7]. Anticholinesterases drugs act mainly by inhibiting acetylcholinesterase and butyryl cholinesterase, prolonging the existence of acetylcholine at the motor end-plate [8]. Additionally, anticholinesterases may have a direct agonistic effect by increasing the release of acetylcholine from presynaptic nerve terminals [9]. For, edrophonium the maximum effective dose is 1.0-1.5mg/kg and for neostigmine, is 60-80μg/kg [8]. The use of two antagonists together is avoided as they are not additive and insufficient reversal can occur. It is not sensible to administer extra anticholinesterase if maximal doses of edrophonium (1.5mg/ kg), neostigmine (70μg/kg), or pyridostigmine (350μg/kg) fail to antagonize the residual blockade and might in turn increase the weakness [9]. They are combined with atropine or glycopyrrolate in order to counteract the muscarinic side-effects of these drugs. Neostigmine is the most potent and the preferred drug [9]. Highdose neostigmine or unnecessary use of neostigmine could interpret to increased post-operative respiratory morbidity [10,11]. Current rules identify the use of reversal with neostigmine based on the train of four (TOF) monitoring with the neuromuscular monitor. Neostigmine can be given for reversal in patients: who were receiving drugs which enhance the action of NMBAs (inhalational agents). The reversal should not be given in case of TOF counts four in patients receiving anaesthetic drugs which do not boost the blockade by NMBAs (intravenous anaesthetics) [10,11]. Moreover, the rules also identify that if the TOF counts less than 2 reversal should not be delayed. A lower dose of neostigmine (20μg/kg) must be considered if TOF counts four and no fade is apparent or if TOF ratio is 0.4:0.9 on qualitative neuromuscular monitoring [12]. Neostigmine is a cholinesterase inhibitors and it is wildly used in Libya as indicated in the literature as reversal agents for NMBAs [13,14]. Sugammadex, which is a novel agent for the reversal of neuromuscular blockade, is adapted gamma-cyclodextrin. Sugammadex is able to form a complex with rocuronium, eradicates it from the circulation and terminates neuromuscular blockade [15]. Sugammadex is a very safe agent with a little risk of serious side effects [16]. The high cost of sugammadex, which is one of the costliest drugs in anesthesia practice, prevents it from being used in Libya as a standard neuromuscular reversal drug. Even though it has been suggested by many doctors in Libya that the cost of sugammadex use in anesthesia could be reduced by shortening the duration of recovery [17,18], further clinical studies on sugammadex in Libya are needed to introduce it to the governmental and private hospitals. to know more click on below link.

https://lupinepublishers.com/pharmacology-clinical-research-journal/fulltext/reversal-of-rocuronium-induced-neuromuscular.ID.000103.php

For more Lupine Publishers Open Access Journals Please visit our website: https://lupinepublishers.com/

For more Journal of Pharmacology articles Please Click Here: https://lupinepublishers.com/pharmacology-clinical-research-journal/

 

LOJ Pharmacology & Clinical Research (LOJPCR) - Lupine Publishers

LOJ Pharmacology & Clinical Research (LOJPCR) is an international open-access journal with a peer reviewed, primary aim of exploring all areas of Pharmacology & Clinical research. The main aim of this journal is on research that advances understanding of existing and new psychopharmacological agents including their mode of action and clinical application or provides insights into the biological basis of psychiatric disorders and thereby advances their pharmacological and clinical treatment. The main scope of this journal is to publish high quality original research work based on standards of expert review and excellence in all aspects of clinical studies related to the field of pharmacology, Clinical Research that which creates a platform for the authors to contribute their eminent manuscripts towards the journal.

http://www.lupinepublishers.com/lojpcr/